HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate Enters Pro Skin-Care Market With PCA Skin, EltaMD Buys

This article was originally published in The Rose Sheet

Executive Summary

The oral-care leader picks up two of the fastest-growing names in professional skin care with separate deals expected to close in the first quarter of 2018, according to a Dec. 18 announcement.

You may also be interested in...



Colgate Doubles Down On Premium Skin Care With $1.7bn Filorga Acquisition

Back in April, CEO Noel Wallace noted Colgate’s interest in further skin-care M&A during his first quarterly presentation at the firm’s helm. The Filorga purchase is significantly bigger than 2018 deals that whet Colgate’s appetite for high-growth, high-margin skin care and represents a gateway to the fast-growing travel retail channel.

Colgate’s Prestige Skin-Care Acquisitions Inspire Interest In Similar Deals

Colgate-Palmolive plans to “dial up investments” in prestige skin-care brands EltaMD and PCA Skin, which helped drive North American sales up 3% in the first quarter, says CEO Noel Wallace during his first quarterly presentation as CEO.

Colgate Attacking Fiscal 2018 Second Half With Urgency, Not Panic

Organic growth remains difficult to find for Colgate in a challenging macro environment marked by slowing emerging markets and unfavorable foreign exchange. However, the firm is optimistic about its continuing Naturals expansion, recent professional skin-care pickups and planned pricing initiatives going into the fiscal 2018 second half.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel